FDA approves Tryngolza as adjunct to diet for familial chylomicronemia syndrome
Tryngolza (olezarsen) has been approved by the U.S. Food and Drug Administration as an adjunct to diet to reduce ...
McKnight's Long-Term Care News1 天
FDA approves first generic liraglutide once-daily injection
The US Food and Drug Administration has approved the first generic referencing Victoza (liraglutide; Hikma Pharmaceuticals), ...
FDA approves weight-loss drug Zepbound for obstructive sleep apnea
The US Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...
FDA approves weight-loss drug Zepbound to treat sleep apnea
The Food and Drug Administration on Friday approved Eli Lilly’s weight-loss drug Zepbound to treat sleep apnea, a common but ...
来自MSN11 天
FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S.
The Food and Drug Administration approved Eli Lilly's blockbuster weight loss drug ... Zepbound should be used in combination ...
FDA approves first medication for obstructive sleep apnea, which also promotes weight loss
The FDA approved a new drug treatment for obstructive sleep apnea that improves the condition through weight loss. Sleep ...
New York Post6 天
FDA approves first medication for obstructive sleep apnea — which also promotes weight loss
20, the FDA announced that the agency has approved Eli Lilly’s Zepbound ... The agency said that along with the drug, a reduced-calorie diet and increased physical activity should also be ...
Medscape8 天
FDA Approves Second Generic Daily GLP-1 Drug for T2D
The US Food and Drug Administration approved a generic once-daily injectable version of the glucagon-like peptide-1 receptor ...
FDA approves anti-obesity drug as first sleep apnea medication
The US FDA approved Eli Lilly's Zepbound as the first ever medication for obstructive sleep apnea for patients who also have ...
WebMD8 天
FDA Approves Zepbound for Obstructive Sleep Apnea
FDA has approved the first prescription drug, Zepbound, for treating moderate to severe obstructive sleep apnea (OSA) in ...